Philip F Halloran
Overview
Explore the profile of Philip F Halloran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
4338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madill-Thomsen K, Venner J, Parsons D, Famulski K, Thiesen A, Hoque S, et al.
Sci Rep
. 2025 Mar;
15(1):8342.
PMID: 40064933
The expanding portfolio of targeted therapies for ulcerative colitis (UC) suggests that a more precise approach to defining disease activity will aid clinical decision-making. This prospective study used genome-wide microarrays...
2.
3.
Madill-Thomsen K, Gauthier P, Abouljoud M, Bhati C, Bruno D, Ciszek M, et al.
Transplantation
. 2025 Jan;
PMID: 39780312
Background: Initial analysis of liver transplant biopsies in the INTERLIVER study (ClinicalTrials.gov; unique identifier NCT03193151) using rejection-associated transcripts failed to find an antibody-mediated rejection state (ie, rich in natural killer...
4.
Hruba P, Klema J, Mrazova P, Girmanova E, Jaklova K, Voska L, et al.
Transplant Direct
. 2024 Dec;
11(1):e1741.
PMID: 39687512
Background: Presensitized patients with circulating donor-specific antibodies (DSAs) before transplantation are at risk for antibody-mediated rejection (AMR). Peritransplant desensitization mitigates but does not eliminate the alloimmune response. We examined the...
5.
Akifova A, Budde K, Amann K, Buettner-Herold M, Choi M, Oellerich M, et al.
Nephrol Dial Transplant
. 2024 Dec;
PMID: 39673311
Background And Hypothesis: Donor-derived cell-free DNA (dd-cfDNA) shows good diagnostic performance for the detection of antibody-mediated rejection (AMR) in kidney transplant recipients (KTR). However, the clinical benefits of dd-cfDNA monitoring...
6.
Bohmig G, Patel U, Halloran P
N Engl J Med
. 2024 Sep;
391(12):1162-1163.
PMID: 39321372
No abstract available.
7.
Halloran P, Madill-Thomsen K, Bohmig G, Bromberg J, Budde K, Barner M, et al.
Am J Transplant
. 2024 Aug;
25(1):72-87.
PMID: 39117038
Most kidney transplant patients who undergo biopsies are classified as having no rejection based on consensus thresholds. However, we hypothesized that because these patients have normal adaptive immune systems, T...
8.
Viklicky O, Hruba P, Novotny M, Kment M, Roder M, Halloran P, et al.
Transplant Direct
. 2024 Jul;
10(8):e1685.
PMID: 39035116
No abstract available.
9.
Diebold M, Farkash E, Barnes J, Regele H, Kozakowski N, Schatzl M, et al.
Transpl Int
. 2024 Jul;
37:13209.
PMID: 38979120
Transcript analyses highlight an important contribution of natural killer (NK) cells to microvascular inflammation (MVI) in antibody-mediated rejection (ABMR), but only few immunohistologic studies have quantified their spatial distribution within...
10.
Madill-Thomsen K, Halloran P
Clin Sci (Lond)
. 2024 May;
138(11):663-685.
PMID: 38819301
There is a major unmet need for improved accuracy and precision in the assessment of transplant rejection and tissue injury. Diagnoses relying on histologic and visual assessments demonstrate significant variation...